Oyster Point Pharma Announces Positive Study Results From Its Nasal Spray Against Covid-19

(RTTNews) - Oyster Point Pharma, Inc. (OYST) Thursday announced positive preclinical data from the study of OC-01 (varenicline), the company's nasal spray against SARS-CoV-2 and the alpha and beta variants, in non-human primates and in vitro models.

The company said OC-01 nasal spray inhibited viral replication in the nose within 24 hours of infection with SARS-CoV-2.

Additionally, OC-02 (simpinicline), a highly selective nicotinic acetylcholine receptor agonist showed potent antiviral activity against the SARS-CoV-2 variants in in vitro study.

"Given the results of both the in vivo and in vitro studies, OC-01 (varenicline) nasal spray and OC-02 (simpinicline) nasal spray warrant further investigation as an antiviral agent for pre-exposure prophylaxis, post-exposure prophylaxis, and/or prevention of transmission of SARS-CoV-2. Additional in vivo and in vitro studies are ongoing," the company said.

Oyster Point Pharma plans to present data at the upcoming Analyst Day, scheduled on July 15, 2021.